AU2014301629B2 - Novel antibody frameworks - Google Patents

Novel antibody frameworks Download PDF

Info

Publication number
AU2014301629B2
AU2014301629B2 AU2014301629A AU2014301629A AU2014301629B2 AU 2014301629 B2 AU2014301629 B2 AU 2014301629B2 AU 2014301629 A AU2014301629 A AU 2014301629A AU 2014301629 A AU2014301629 A AU 2014301629A AU 2014301629 B2 AU2014301629 B2 AU 2014301629B2
Authority
AU
Australia
Prior art keywords
sequence
human
framework region
nucleic acid
germ line
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014301629A
Other languages
English (en)
Other versions
AU2014301629A1 (en
Inventor
Sebastian Meyer
David Urech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Numab Therapeutics AG
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of AU2014301629A1 publication Critical patent/AU2014301629A1/en
Assigned to NUMAB INNOVATION AG reassignment NUMAB INNOVATION AG Alteration of Name(s) of Applicant(s) under S113 Assignors: NUMAB AG
Assigned to Numab Therapeutics AG reassignment Numab Therapeutics AG Amend patent request/document other than specification (104) Assignors: NUMAB INNOVATION AG
Application granted granted Critical
Publication of AU2014301629B2 publication Critical patent/AU2014301629B2/en
Priority to AU2020202770A priority Critical patent/AU2020202770B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2014301629A 2013-06-26 2014-06-26 Novel antibody frameworks Active AU2014301629B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020202770A AU2020202770B2 (en) 2013-06-26 2020-04-27 Novel antibody frameworks

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003264.2 2013-06-26
EP13003264 2013-06-26
PCT/EP2014/001730 WO2014206561A1 (en) 2013-06-26 2014-06-26 Novel antibody frameworks

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020202770A Division AU2020202770B2 (en) 2013-06-26 2020-04-27 Novel antibody frameworks

Publications (2)

Publication Number Publication Date
AU2014301629A1 AU2014301629A1 (en) 2015-12-10
AU2014301629B2 true AU2014301629B2 (en) 2020-02-06

Family

ID=48699516

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014301629A Active AU2014301629B2 (en) 2013-06-26 2014-06-26 Novel antibody frameworks
AU2020202770A Active AU2020202770B2 (en) 2013-06-26 2020-04-27 Novel antibody frameworks

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020202770A Active AU2020202770B2 (en) 2013-06-26 2020-04-27 Novel antibody frameworks

Country Status (12)

Country Link
US (3) US10174102B2 (OSRAM)
EP (1) EP3013864A1 (OSRAM)
JP (4) JP6708544B2 (OSRAM)
KR (4) KR20240000622A (OSRAM)
CN (2) CN105579472B (OSRAM)
AU (2) AU2014301629B2 (OSRAM)
CA (1) CA2914829A1 (OSRAM)
HK (1) HK1218549A1 (OSRAM)
IL (3) IL243311B (OSRAM)
NZ (1) NZ714320A (OSRAM)
SG (2) SG10201811017QA (OSRAM)
WO (1) WO2014206561A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG Novel antibody frameworks
CN115057936B (zh) 2015-06-15 2025-05-30 努玛治疗有限公司 异源二聚体多特异性抗体形式
BR112018067698A2 (pt) 2016-02-25 2019-01-08 Cell Medica Switzerland Ag células modificadas para imunoterapia
CA3011500A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnfalpha-antibodies and functional fragments thereof
HUE052869T2 (hu) 2016-03-17 2021-05-28 Tillotts Pharma Ag TNF-ellenes alfa-antitestek és ezek funkcionális fragmentjei
JP7184746B2 (ja) 2016-03-17 2022-12-06 ヌマブ イノヴェイション アーゲー 抗ＴＮＦα抗体およびそれらの機能的断片
LT3219726T (lt) 2016-03-17 2021-01-25 Tillotts Pharma Ag Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
WO2017158101A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
GB201621591D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Antibody molecules and method
US11319371B2 (en) 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
ES2967739T3 (es) 2017-06-05 2024-05-03 Numab Therapeutics AG Formato de anticuerpo heterodimérico multiespecífico dirigido al menos a CD3 y a HSA
AU2018280679B2 (en) * 2017-06-05 2025-04-24 Numab Therapeutics AG Novel anti-HSA antibodies
EP3645049A4 (en) 2017-06-25 2021-06-30 Systimmune, Inc. MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF
CN110799540B (zh) * 2017-06-25 2024-02-13 西雅图免疫公司 多特异性抗体及其制备和使用方法
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
CN113631574B (zh) 2019-01-31 2025-03-04 努玛治疗有限公司 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
EP4271413A4 (en) * 2020-12-30 2025-07-30 Ascendo Biotechnology Inc MONOCLONAL ANTIBODY AGAINST HUMAN MAC-1 AND ITS USES
WO2022171771A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
CA3213283A1 (en) 2021-03-11 2022-09-15 IgGenix, Inc. Methods and systems for predicting allergic response
AR128065A1 (es) 2021-12-22 2024-03-20 Cdr Life Ag Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
WO2024098026A2 (en) * 2022-11-04 2024-05-10 Mink Therapeutics, Inc. B-cell maturation antigen (bcma) chimeric antigen receptor invariant natural killer t cells and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
CN101868477A (zh) 2007-05-21 2010-10-20 奥尔德生物制药公司 新型兔抗体人源化方法和人源化的兔抗体
WO2009000099A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
LT3444274T (lt) * 2008-06-25 2021-03-25 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys tnf
BRPI0914663A2 (pt) 2008-06-25 2015-10-20 Esbatech Alcon Biomed Res Unit humanização de anticorpos de coelho usando uma estrutura de anticorpo universal
CN110372792A (zh) * 2008-06-25 2019-10-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
US8193235B2 (en) 2009-06-12 2012-06-05 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
CA2798120A1 (en) * 2010-04-30 2011-11-03 Paul P. Tamburini Antibodies having reduced immunogenicity in a human
EP2726504A1 (en) * 2011-05-27 2014-05-07 Dutalys Antibodies with improved folding stability
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG Novel antibody frameworks
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BORRAS, L. ET AL, "Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies", JOURNAL OF BIOLOGICAL CHEMISTRY, (2010), vol. 285, no. 12, pages 9054 - 9066 *

Also Published As

Publication number Publication date
AU2014301629A1 (en) 2015-12-10
KR20160024923A (ko) 2016-03-07
KR20220029763A (ko) 2022-03-08
KR102286053B1 (ko) 2021-08-04
HK1218549A1 (zh) 2017-02-24
JP2022028659A (ja) 2022-02-16
IL293477A (en) 2022-08-01
IL293477B1 (en) 2024-07-01
IL243311B (en) 2022-07-01
JP2024026176A (ja) 2024-02-28
CN113943366B (zh) 2024-12-13
CN105579472A (zh) 2016-05-11
US11427628B2 (en) 2022-08-30
NZ714320A (en) 2022-02-25
CN113943366A (zh) 2022-01-18
CA2914829A1 (en) 2014-12-31
IL293477B2 (en) 2024-11-01
JP6708544B2 (ja) 2020-06-10
US20190119359A1 (en) 2019-04-25
JP2016523537A (ja) 2016-08-12
US20230212265A1 (en) 2023-07-06
JP2019201643A (ja) 2019-11-28
KR20240000622A (ko) 2024-01-02
SG11201509899PA (en) 2016-01-28
WO2014206561A1 (en) 2014-12-31
IL313351A (en) 2024-08-01
SG10201811017QA (en) 2019-01-30
AU2020202770A1 (en) 2020-05-14
AU2020202770B2 (en) 2023-01-05
IL243311A0 (en) 2016-03-31
EP3013864A1 (en) 2016-05-04
CN105579472B (zh) 2021-10-22
US20160130326A1 (en) 2016-05-12
WO2014206561A8 (en) 2016-02-18
KR20210097829A (ko) 2021-08-09
US10174102B2 (en) 2019-01-08

Similar Documents

Publication Publication Date Title
US20230212265A1 (en) Novel antibody frameworks
AU2018335823B2 (en) Novel stable antibody variable domain framework combinations
JP2016523537A5 (OSRAM)
US11365240B2 (en) Anti-HSA antibodies
WO2018224439A1 (en) Novel anti-hsa antibodies
HK40023336B (en) Anti-hsa antibodies
HK40023336A (en) Anti-hsa antibodies

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: NUMAB INNOVATION AG

Free format text: FORMER NAME(S): NUMAB AG

HB Alteration of name in register

Owner name: NUMAB THERAPEUTICS AG

Free format text: FORMER NAME(S): NUMAB INNOVATION AG

FGA Letters patent sealed or granted (standard patent)